FORM D

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

# FORM D

OMB APPROVAL
OMB Number: 3235-0076
Expires: April 30, 2008
Estimated average burden
hours per response.......16.00

SEC USE ONLY

DE



NOTICE OF SALE OF SECURITIES
PURSUANT TO REGULATION D,
SECTION 4(6), AND/OR
UNIFORM LIMITED OFFERING EXEMPTION

07087106		
£ ,	in amendment and name has changed, and indicate change.) ies B-1 Convertible Preferred Stock	
Filing under (Check box(es) that apply): Type of Filing: New Filing	□ Rule 504 □ Rule 505 ☑ Rule 506 □ Section 4(6) □ ULOE □ Amendment □ DEC	ECEIVED
	A. BASIC IDENTIFICATION DATA	6 1 8083 T
1. Enter the information requested about th	ie issuer (a)	
Name of Issuer (☐ check if this is <b>Pervasis Therapeutics, Inc.</b>	an amendment and name has changed, and indicate change.)	36 CUDI
Address of Executive Offices One Kendall Square, Building 600, 2		
Address of Principal Business Operations (if different from Executive Offices)	(Number and Street, City, State, Zip Code)  same  Telephone Number (Included same)	•
Brief Description of Business The Corporation develops, manufac	tures, markets and sells biotechnology products and services.	PROCESSE
Type of Business Organization  ⊠ corporation  □ business trust	☐ limited partnership, already formed ☐ other (please specify): ☐ limited partnership, to be formed	JAN 1 0 2008
Actual or Estimated Date of Incorpora	ation or Organization:    Month   Year	THOMSUN FINANCIAL

#### General Instructions

#### Federal

Who Must File: All issuers making an offering of securities in reliance on an exemption under Regulation D or Section 4(6), 17 CFR 230.501 et seq. or 15 U.S.C. 77d(6).

CN for Canada; FN for other foreign jurisdiction)

When To File: A notice must be filed no later than 15 days after the first sale of securities in the offering. A notice is deemed filed with the U.S. Securities and Exchange Commission (SEC) on the earlier of the date it is received by the SEC at the address given below or, if received at that address after the date on which it is due, on the date it was mailed by United States registered or certified mail to that address.

Where to File: U.S. Securities and Exchange Commission, 450 Fifth Street, N.W., Washington, D.C. 20549.

Copies Required: Five (5) copies of this notice must be filed with the SEC, one of which must be manually signed. Any copies not manually signed must be photocopies of the manually signed copy or bear typed or printed signatures.

Information Required: A new filing must contain all information requested. Amendments need only report the name of the issuer and offering, any changes thereto, the information requested in Part C, and any material changes from the information previously supplied in Parts A and B. Part E and the Appendix need not be filed with the SEC.

Filing Fee: There is no federal filing fee.

#### State

This notice shall be used to indicate reliance on the Uniform Limited Offering Exemption (ULOE) for sales of securities in those states that have adopted ULOE and that have adopted this form. Issuers relying on the ULOE must file a separate notice with the Securities Administrator in each state where sales are to be, or have been made. If a state requires the payment of a fee as a precondition to the claim for the exemption, a fee in the proper amount shall accompany this form. This notice shall be filed in the appropriate states in accordance with state law. The Appendix to the notice constitutes a part of this notice and must be completed.

## **ATTENTION**

Failure to file notice in the appropriate states will not result in a loss of the federal exemption. Conversely, failure to file the appropriate federal notice will not result in a loss of an available state exemption unless such exemption is predicated on the filing of a federal notice.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

# A. BASIC IDENTIFICATION DATA

- 2. Enter the information requested for the following:
  - Each promoter of the issuer, if the issuer has been organized within the past five years;
  - Each beneficial owner having the power to vote or dispose, or direct the vote or disposition of, 10% or more of a class of equity securities of the issuer;
  - · Each executive officer and director of corporate issuers and of corporate general managing partners of partnership issuers; and
  - Each general and managing partnership of partnership issuers.

Check Box(es) that Apply:	Promoter		Executive Office	r 🖾 Director		General and/or Managing Partner
Full Name (Last name first, if in						
Edelman, Elazer, R.	,_,,					
Business or Residence Address	(Number and Stre	et, City, State, Zip Code)	<u>.</u>			
30 Warren Street				Brookline	MA	02445
Check Box(es) that Apply:	Promoter	⊠ Beneficial Owner	☐ Executive Office	Director		General and/or Managing Partner
Full Name (Last name first, if in	ndividual)					
Langer, Robert S., Jr.						
Business or Residence Address	(Number and Stre	et, City, State, Zip Code)				
98 Montvale Road				Newton	MA	02459
Check Box(es) that Apply:	Promoter	⊠ Beneficial Owner	☐ Executive Office	Director		General and/or Managing Partner
Full Name (Last name first, if ir	ndiviđual)					
Nugent, Helen M.						
Business or Residence Address	(Number and Stre	et, City, State, Zip Code)				
106 Grosvenor Road				Needham	MA	02492
Check Box(es) that Apply:	Promoter	Beneficial Owner		Director		General and/or Managing Partner
Full Name (Last name first, if in	ndividual)					
Vacanti, Joseph P.						
Business or Residence Address	(Number and Stre	et, City, State, Zip Code)				
14 Woodside Road			į	Winchester	MA	01890
Check Box(es) that Apply:	Promoter	☐ Beneficial Owner		r Director		General and/or Managing Partner
Full Name (Last name first, if in	idividual)					
Bollinger, Stephen A.						···
Business or Residence Address	(Number and Stre	et, City, State, Zip Code)				
c/o Pervasis Therapeutics,	Inc., One Kendal	l Square, Building 600, 2	<sup>nd</sup> Floor	Cambridge	MA	02139
Check Box(es) that Apply:	Promoter	☐ Beneficial Owner	☐ Executive Office	Director		General and/or Managing Partner
Full Name (Last name first, if ir	idividual)					
Collier, Earl M., Jr.						
Business or Residence Address	•	•				00440
c/o Genzyme Corporation,	<del></del>	<del></del>		Cambridge	MA	O2142
Check Box(es) that Apply:	Promoter	☐ Beneficial Owner	Executive Office	Director	<u> </u>	General and/or Managing Partner
Full Name (Last name first, if in Hutt, Peter Barton	idividuai)					
Business or Residence Address	(Number and Stre	et, City, State, Zip Code)				-
c/o Covington & Burling, 12			1	Washington	DC	20004-2401
Check Box(es) that Apply:	Promoter	☐ Beneficial Owner	☐ Executive Office	Director		General and/or Managing Partner
Full Name (Last name first, if in	ndividual)					
Higgins, Robert F.						
Business or Residence Address	(Number and Stre	et, City, State, Zip Code)				
c/o Highland Capital Partne	ers, 92 Hayden A	venue		exington	MA	02421

Check Box(es) that Apply:	Promoter	☐ Beneficial Owner		er 🛮 Director		General and/or Managing Partner
Full Name (Last name first, if ir	ndividual)					
Nashat, Amir H.						
Business or Residence Address	(Number and Street,	City, State, Zip Code)				
c/o Pervasis Therapeutics,	Inc., One Kendall S	Square, Building 600, 2	<sup>nd</sup> Floor	Cambridge	MA	02139
Check Box(es) that Apply:	Promoter	☐ Beneficial Owner	☐ Executive Office	er 🔯 Director		General and/or Managing Partner
Full Name (Last name first, if in	ndividual)				-	
Kania, Edwin M., Jr.						
Business or Residence Address	(Number and Street,	City, State, Zip Code)				
c/o Flagship Ventures, One	Memorial Drive, 7t	h Floor		Cambridge	MA	02142
Check Box(es) that Apply:	Promoter	Beneticial Owner	Executive Office	er 🔲 Director		General and/or Managing Partner
Full Name (Last name first, if ir	idividual)					
Polaris Venture Partners IV	, L.P.					
Business or Residence Address	(Number and Street,	City, State, Zip Code)				•
1000 Winter Street, Suite 3	350			Waltham	MA	02451
Check Box(es) that Apply:	Promoter	🛚 Beneficial Owner	☐ Executive Office	er 🔲 Director		General and/or Managing Partner
Full Name (Last name first, if ir	ndividual)					
Applied Genomic Technology	gy Capital Fund, L	.P.				
Business or Residence Address	(Number and Street,	City, State, Zip Code)		<del></del>		
One Memorial Drive, 7th Flo	oor			Cambridge	MA	02142
Check Box(es) that Apply:	☐ Promoter	Beneficial Owner	☐ Executive Office	er Director		General and/or Managing Partner
Full Name (Last name first, if ir	idividual)					
Highland Capital Partners \	/I Limited Partners	hip				
Business or Residence Address	(Number and Street,	City, State, Zip Code)				
92 Hayden Avenue				Lexington	MA	02421

											<del> </del>			
				<u>B.</u>	INFORMA	ATION ABO	OUT OFFE	RING						
1. Has th	ne issuer solo	d, or does th				dited investo Column 2, if				• • • • •		Yes . $\square$	No ⊠	
2. What	2. What is the minimum investment that will be accepted from any individual?											. \$ N/A		
3. Does	<ul><li>3. Does the offering permit joint ownership of a single unit?</li><li>4. Enter the information requested for each person who has been or will be paid or given, directly or indirectly, any</li></ul>											Yes . 🖾	No	
comr If a p or sta	nission or si erson to be ates, list the	milar remu listed is an name of th	neration for associated p broker or o	solicitation erson or age lealer. If me	of purchase int of a brok ore than fiv	es in connec er or dealer e (5) person	tion with sa registered v s to be liste	iles of s vith the	ecuritie SEC an	s in the d/or wi	offering. tha state		Р. 11	
	ne (Last nan		set forth the	intormation	for that bro	ker or deale	r only.	<del></del>		<del></del>	<del></del>	NOT A	oplicable	<u> </u>
i un ivan	ne (Last nati	ic 1115t, 11 11	idividual)											
Business	or Residen	ce Address	(Number an	d Street, Cit	y, State, Zi <sub>l</sub>	o Code)								
Name of	Associated	Broker or l	Dealer							•				
- C	11/1 ! D	7			0.11.1.0			<del></del> .	·· · <u>·</u>					
States in			las Solicited r check indiv									☐ All S	itates	
(AL)	[AK] 🔲	[AZ] 🔲	[AR]	[CA] 🔲	[CO] 🗆	[CT]	(DE)	[DC]	☐ [FI		[GA] 🗌	[HI] 🔲	[ID]	
[IL]   [MT]	[NE]	[IA]   [NV]	[KS]       [NH]	[KA]	[LA]	[ME]    [NY]	[MD]   [NC]	[MA] [ND]			[MN]   [OK]	[MS]   [OR]	[MO] [PA]	
[RI] 🔲	[SC]	[SD] []		TXI 🗆	[טדן 🗀	[M] [	[VA]	[WA]				WY 🗀	[PR]	<u> </u>
Full Nan	ne (Last nan	ne first, if ir	idividual)											
Business	or Residen	e Address	(Number and	d Street, Cit	y, State, Zip	Code)								
Name of	Associated	Broker or I	Dealer											
						<u> </u>								
States in			las Solicited r check indiv									☐ All S	tates	
	(Olleon 11	ii Otales o	CHEEK HIGH	idual otates	,,	<i></i>				• • • • •	• • • • • • • •		iaics	
[AL]	[AK]    [IN]	[AZ]	[AR] 🗍 [KS] 📋	[CA]     [KY]	[CO]   [LA]	[CT]       [ME]	[DE]   [MD]	[DC] [MA]	[F]   [M		[GA] 🗌 [MN] 🔲	[HI] [] [MS] []	[ID] [MO]	
[MT] 🔲	[NE]	[VV]	[NH] 🔲	[ил] 🗖	[MM]	[ҮИ]	[NC]	[ND]		-j □	[ок] 🔲	[OR] 🗌	[PA]	
[RI] []	[SC]  ne (Last nam	[SD] 🔲	[TN] []	[TX] 🗆	[UT]	[√T] □	[VA] 🗌	[WA]	<u>w</u>	<u>VI LI</u>	[WI] 🔲	[WY] 🗆	[PR]	
	ic (East Hair		arriduur)											
Business	or Residence	e Address	(Number and	l Street, Cit	y , State, Zi	p Code)		-			·			
Name of	Associated	Broker or I	Dealer	<u>.</u>										—
<u></u>											······································			
States in			las Solicited check indiv									☐ All St	ates	_
[AL]	[AK]	[AZ] 🗌	[AR] 🔲	[CA]	[CO] [	[СТ] 🔲	[DE] 🔲	[DC]	☐ [Fi]		[GA] 🗍	(HI) 🗆	[ID]	
	[IN]	[IA]	[KS]	[KY]	[LA]	[ME]   [NY]   [VT]	[MD] [DM]	[MA] [ND]		]	[WN]	[MS] [OR] [OR]		

(Use blank sheet, or copy and use additional copies of this sheet, as necessary)

C. OFFERING PRICE, NUMBER OF INVESTORS, EXPENSES AND USE C	,, ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	
Enter the aggregate offering price of securities included in this offering and the total amount already sold. Enter "0" if answer is "none" or "zero." If the transaction is an exchange offering, check this box  and indicate in the columns below the amounts of the securities offered for exchange and		
	Aggregate	Amount Already
	_	Sold
	_	\$ <u>0</u>
☐ Common ☑ Preferred	-	\$ <u>9,749,998.50</u>
Convertible Securities (including warrants)	\$ <u>0</u>	\$ <u>0</u>
Partnership Interests	\$ <u>0</u>	\$ <u>0</u>
Other (Specify)	\$ <u>0</u>	\$ <u>0</u>
Total	\$ <u>9,749,998.50</u>	\$ <u>9,749,998.50</u>
Answer also in Appendix, Column 3, if filing under ULOE.		
offering and the aggregate dollar amounts of their purchases. For offerings under Rule 504, indicate		Aggregate Dollar Amount of Purchases
Accredited Investors	<u>8</u>	\$ <u>9,749,998.50</u>
Non-accredited Investors	<u>0</u>	\$ <u>0</u>
Total (for filing under Rule 504 only)	<u>N/A</u>	\$ <u>N/A</u>
Type of offering	Type of Security	Dollar Amount Sold
Rule 505	<u>N/A</u>	\$ <u>N/A</u>
Regulation A	<u>N/A</u>	\$ <u>N/A</u>
Rule 504	N/A	\$ <u>N/A</u>
Total	N/A	\$ <u>N/A</u>
in this offering. Exclude amounts relating solely to organization expenses of the issuer. The information		
Transfer Agent's Fees		\$ <u>N/A</u>
Printing and Engraving Costs		\$ <u>N/A</u>
Legal Fces		\$ <u>43,000.00</u>
Accounting Fees		\$ <u>N/A</u>
Engineering Fees.		\$ <u>N/A</u>
Sales Commissions (specify finders' fees separately)		\$ <u>N/A</u>
		\$N/A
	_	<del></del>
	Enter the aggregate offering price of securities included in this offering and the total amount already sold. Enter 70° if answer is "none" or "zero." If the transaction is an exchange offering, check this box   and indicate in the columns below the amounts of the securities offered for exchange and already exchanged.  Type of Security   Debt   Equity.   Gommon   Preferred   Preferred   Convertible Securities (including warrants)   Partnership Interests.   Other (Specify   Answer also in Appendix, Column 3, if filling under ULOE.   Enter the number of accredited and non-accredited investors who have purchased securities in this offering and the aggregate dollar amounts of their purchases. For offerings under Rule 504, indicate the number of persons who have purchased securities and the aggregate dollar amount of their purchases on the total lines. Enter "0" if answer is "none" or "zero."   Accredited Investors   Non-accredited Investors   Total (for filing under Rule 504 only)   Answer also in Appendix, Column 4, if filing under ULOE.   If this filing is for an offering under Rule 504 or 505, enter the information requested for all securities sold by the issuer, to date, in offerings of the types indicated, in the twelve (12) months prior to the first sale of securities in this offering. Classify securities by type listed in Part C - Question 1.  Type of offering Rule 504.   Total   Total	Enter the augreguise offering price of securities included in this offering and the total annual already sold. Eater "0" if answer is "none" or "zero." if the transaction is an exchange offering, check this box   Aggregate Offering Price between the columns below the amounts of the securities offered for exchange and already exchanged.  Type of Security   Offering Price   \$Q   Equity.   \$Q   Equity.   \$Q   Equity.   \$Q   Equity.   \$Q   Equity.   \$Q   Partnership Interests.   \$Q   Other (Specify   \$Q   Total   \$Q   Answer also in Appendix, Column 3, if filing under ULOE.  Enter the number of accredited and non-accredited investors who have purchased securities in this offering and the aggregate dollar amounts of their purchases. For offerings under Rule 504, indicate the number of persons who have purchased securities and the aggregate dollar amounts of their purchases. For offerings under Rule 504, indicate the number of persons who have purchased securities and the aggregate dollar amounts of their purchases. For offerings under Rule 504, indicate the number of persons who have purchased securities and the aggregate dollar amount of their purchases on the total lines. Enter "0" if answer is "none" or "zero."  Accredited Investors

_	C. OFFERING	PRICE, NUMBER OF INVESTORS, EXPE	ENSES AND USE O	OF PROCEEDS	
		aggregate offering price given in response to Pase to Part C Question 4.a. This difference is			\$ <u>9,706,998.50</u>
5.	each of the purposes shown. If the ar	usted gross proceeds to the issuer used or prop nount for any purpose is not known, furnish an The total of the payments listed must equal onse to Part C- Question 4.b. above.	estimate and check	Payments to Officers, Directors, &	Payments To
	Salaries and fees			Affiliates \$0	Others  \$\sum_ \\$0\$
	Purchase of real estate		🗆	\$ <u>0</u>	□ \$ <u>0</u>
	Purchase, rental or leasing and in	nstallation of machinery and equipment	🗆	\$ <u>0</u>	□ \$ <u>0</u>
	Construction or leasing of plant	buildings and facilities		\$ <u>0</u>	□ \$ <u>0</u>
	offering that may be used in excissuer pursuant to a merger)  Repayment of indebtedness	including the value of securities involved in this nange for the assets or securities of another		\$ <u>0</u>	□ \$ <u>0</u> □ \$ <u>0</u> □ \$ <u>0</u> □ \$ <u>9,706,998.50</u>
	Other (specify):			\$ <u>0</u>	□ \$ <u>0</u>
	Column Totals		🗖	\$ <u>0</u>	□ \$0 ⊠ \$ <u>9,706,998.50</u>
	Total Payments Listed (column t	otals added)		<b>⊠</b> \$ <u>9,706,</u> 9	<u>998.50</u>
_		D. FEDERAL SIGNATUR	E		
sig	nature constitutes an undertaking by tl	be signed by the undersigned duly authorized ne issuer to furnish to the U.S. Securities and non-accredited investor pursuant to paragraph (	<b>Exchange Commiss</b>		
lss	uer (Print or Type)	Signature	Date		
	rvasis Therapeutics, Inc.	- Angulul	Decem	ber 28, 2007	
Na	me of Signer (Print or Type)	Title of Signer (Print or Type)			
Je	ffrey L. Quillen	Assistant Secretary			

ATTENTION Intentional misstatements or omissions of fact constitute federal criminal violations. (See 18 U.S.C. 1001.)

	E. STATE SIGNATURE								
Is any party described in 17 CFR 230.262 pres of such rule?	sently subject to any disqualification provisions	Yes No □ ⊠							
	See Appendix, Column 5, for state response								
<ol> <li>The undersigned issuer hereby undertakes to furnish to any state administrator of any state in which this notice is filed, a notice on Form D (17 CFR 239.500) at such times as required by state law.</li> </ol>									
<ol> <li>The undersigned issuer hereby undertakes to furnish to the state administrators, upon written request, information furnished by the issuer to offerees.</li> </ol>									
Offering Exemption (ULOE) of the state in	4. The undersigned issuer represents that the issuer is familiar with the conditions that must be satisfied to be entitled to the Uniform Limited Offering Exemption (ULOE) of the state in which this notice is filed and understands that the issuer claiming the availability of this exemption has the burden of establishing that these conditions have been satisfied.								
The issuer has read this notification and know undersigned duly authorized person.	The issuer has read this notification and knows the contents to be true and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.								
Issuer (Print or Type)  Pervasis Therapeutics, Inc.  Signature  December 28, 2007									
Name (Print or Type)	Title (Print or Type)	242000 20, 200							
Jeffrey L. Quillen	Assistant Secretary								

#### Instruction:

Print the name and title of the signing representative under his signature for the state portion of this form. One copy of every notice on Form D must be manually signed. Any copies not manually signed must be photocopies of the manually signed copy or bear typed or printed signatures.

## APPENDIX 2 3 Disqualification under State ULOE Type of security (if yes, attach and aggregate offering price Intend to sell explanation of to non-accredited Type of investor and waiver granted) investors in State offered in state amount purchased in State (Part E-Item 1) (Part B-Item1) (Part C-Item I) (Part C-Item 2) Number of Number of Non-Accredited Accredited Investors State Yes No Investors Amount Amount Yes No ALΑK ΑZ AR $\mathsf{C}\mathsf{A}$ CO CTDE DC FL $\mathsf{G}\mathsf{A}$ H! ID IL ΙN lΑ KS KYLA $\mathsf{ME}$ MD Series B-1 Convertible Preferred: Aggregate \$9,749,998.50 MA Х 8 \$9,749,998.50 0 0 Х ΜI MN

MS

# APPENDIX 2 3 4 Disqualification Type of security under State ULOE Intend to sell and aggregate offering price (if yes, attach to non-accredited Type of investor and explanation of investors in State offered in state amount purchased in State waiver granted) (Part B-Item1) (Part C-Item 2) (Part C-Item 1) (Part E-Item 1) Number of Number of Accredited Non-Accredited State Yes No Investors Investors Yes No Amount Amount МО MTNE NVNHNJ NMNYNC NDОН OK OR PA RΙ SC SD ΤN TX UT VT VA W AWV

WI

				A	PPENDIX					
1	Intend to sell to non-accredited investors in State (Part B-Item1)		Type of security and aggregate offering price offered in state (Part C-Item 1)		Type of investor and amount purchased in State (Part C-Item 2)					
State	Yes	No	(Far C-nem 1)	Number of Accredited Investors	Amount	Number of Non- Accredited Investors	Amount	Yes	No	
WY										
PR										
Other					<del></del>					

